TY - JOUR
T1 - Evaluation of an assay for MGMT gene promoter methylation in glioblastoma samples
AU - Filipits, Martin
AU - Preusser, Matthias
AU - Hainfellner, Johannes A.
AU - Spiegl-Kreinecker, Sabine
AU - Berghoff, Anna S.
AU - Lai, Edwin W.
AU - Kocmond, Kriszten
AU - Kohlway, Andrew
AU - Weidler, Jodi
AU - Bates, Michael
AU - Corless, Christopher
N1 - Publisher Copyright:
© 2020 International Institute of Anticancer Research. All rights reserved.
PY - 2020/11
Y1 - 2020/11
N2 - Background/Aim: To compare the GeneXpert® O6-methylguanine DNA methyltransferase (MGMT) methylation prototype (GX MGMT) assay with pyrosequencing in glioblastomas. Materials and Methods: The MGMT methylation status was retrospectively assessed in formalin-fixed paraffin embedded (FFPE) tumor blocks from 262 glioblastoma patients obtained from three independent cohorts using either a standard of care pyrosequencing laboratory developed test or the GX MGMT assay. Results: The concordance rate was 92.1% (58/63) for Oregon Health and Science University (OSHU) samples, 91.7% (88/96) for Medical University of Vienna (MUV) samples, and 82.5% (85/103) for Kepler University Hospital (KUH) samples. Patients with MGMT promoter hypermethylation assessed by pyrosequencing or the GX MGMT test had a significantly longer overall survival compared to patients without hypermethylation (HR=0.43, 95%CI=0.26-0.72, p=0.001 and HR=0.51, 95%CI=0.31-0.84, p=0.008, respectively). Conclusion: Standardized, simplified, and on-demand testing of MGMT promoter methylation by the GX MGMT assay is feasible.
AB - Background/Aim: To compare the GeneXpert® O6-methylguanine DNA methyltransferase (MGMT) methylation prototype (GX MGMT) assay with pyrosequencing in glioblastomas. Materials and Methods: The MGMT methylation status was retrospectively assessed in formalin-fixed paraffin embedded (FFPE) tumor blocks from 262 glioblastoma patients obtained from three independent cohorts using either a standard of care pyrosequencing laboratory developed test or the GX MGMT assay. Results: The concordance rate was 92.1% (58/63) for Oregon Health and Science University (OSHU) samples, 91.7% (88/96) for Medical University of Vienna (MUV) samples, and 82.5% (85/103) for Kepler University Hospital (KUH) samples. Patients with MGMT promoter hypermethylation assessed by pyrosequencing or the GX MGMT test had a significantly longer overall survival compared to patients without hypermethylation (HR=0.43, 95%CI=0.26-0.72, p=0.001 and HR=0.51, 95%CI=0.31-0.84, p=0.008, respectively). Conclusion: Standardized, simplified, and on-demand testing of MGMT promoter methylation by the GX MGMT assay is feasible.
KW - GeneXpert
KW - Glioblastoma
KW - MGMT promoter methylation
KW - Pyrosequencing
UR - http://www.scopus.com/inward/record.url?scp=85094844296&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85094844296&partnerID=8YFLogxK
U2 - 10.21873/anticanres.14643
DO - 10.21873/anticanres.14643
M3 - Article
C2 - 33109560
AN - SCOPUS:85094844296
SN - 0250-7005
VL - 40
SP - 6229
EP - 6236
JO - Anticancer research
JF - Anticancer research
IS - 11
ER -